Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

EJNMMI Research

Volumn 6, Issue 1, 2016, Pages

  Cheng, Qing ^a   Wållberg, Helena ^a   Grafström, Jonas ^a   Lu, Li ^a,b   Thorell, Jan Olov ^a,b   Hägg Olofsson, Maria ^a   Linder, Stig ^a   Johansson, Katarina ^a   Tegnebratt, Tetyana ^a,b   Arnér, Elias S J ^a   Stone Elander, Sharon ^a,b   Ahlzén, Hanna Stina Martinsson ^a   Ståhl, Stefan ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Affibody molecule; Dual tracer imaging; Epidermal growth factor receptor; Positron emission tomography; Sel tag

Indexed keywords

VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR GROWTH; TUMOR VOLUME;

EID: 84978062632     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-016-0213-8     Document Type: Article

References (51)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9–15.
3. Nedergaard MK, Hedegaard CJ, Poulsen HS. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs. 2012;26:83–99.
4. Gusterson BA, Hunter KD. Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol. 2009;10:522–7.
5. Corcoran EB, Hanson RN. Imaging EGFR and HER2 by PET and SPECT: a review. Med Res Rev. 2014;34:596–643.
6. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009;20:213–26.
7. Tichauer KM, Wang Y, Pongue BW, Liu JTC. Quantitative in vivo cell-surface receptor modeling in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol. 2015;60:R239–69.
8. Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren PÅ. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–7.
9. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–80.
10. Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, et al. Phage display selection of Affibody molecules binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel. 2007;20:189–99.
11. Friedman M, Orlova A, Johansson E, Eriksson TL, Höidén-Guthenberg I, Tolmachev V, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding Affibody molecule. J Mol Biol. 2008;376:1388–402.
12. Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009;50:274–83.
13. 64Cu labeled Affibody protein. Bioconjug Chem. 2010;21:947–54.
14. 18F-labeled Affibody molecule. J Nucl Med. 2012;53:1110–8.
15. 111In]-labeled Affibody molecule Z(EGFR:2377) and cetuximab. Int J Oncol. 2011;38:1137–43.
16. EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37:613–22.
17. Tichauer KM, Diop M, Elliott JT, Samkoe KS, Hasan T, Lawrence KS, et al. Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. Phys Med Biol. 2014;59:2341–51.
18. Gunneriusson E, Nord K, Uhlén M, Nygren PÅ. Affinity maturation of a Taq DNA polymerase specific Affibody by helix shuffling. Protein Eng. 1999;12:873–8.
19. 11C. Nat Protoc. 2006;1:604–13.
20. 11C-labeled Sel-tagged Affibody molecule. J Nucl Med. 2012;53:1446–53.
21. Cleta Croce A, Ferrigno A, Vairetti M, Bertone R, Freitas I, Bottiroli G. Autofluorescence spectroscopy of rat liver during experimental transplantation procedure. An approach for hepatic metabolism assessment. Photochem Photobiol Sci. 2005;4:583–90.
22. Mogensen CE, Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977;37:477–86.
23. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.
24. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–9.
25. Hlatky L, Olesiak M, Hahnfeldt P. Measurement of potential doubling time for human tumor xenografts using cytokinesis block method. Cancer Res. 1996;56:1660–3.
26. Ehling J, Theek B, Gremse F, Baetke F, Möckel D, Maynard J, et al. Micro-CT imaging of tumor angiogenesis: quantitative measures describing micromorphology and vascularization. Am J Pathol. 2014;184:431–41.
27. Bremer C, Mustafa M, Bogdanov Jr A, Ntziachristos V, Petrovsky A, Weissleder R. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology. 2003;226:214–20.
28. Figueiras RG, Padhani AR, Goh VJ, Villanova JC, González SB, Martin CV, et al. Novel oncologic drugs: what they do and how they affect images. Radiographics. 2011;31:2059–91.
29. 11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS One. 2012;7:e42151.
30. Grafström J, Stone-Elander S. Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies. Nucl Med Biol. 2014;41:793–800.
31. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.
32. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421–34.
33. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer. 2009;8:2861–71.
34. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98:316–25.
35. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49:788–95.
36. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–31.
37. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50:1116–23.
38. Tichauer KM, Samkoe KS, Sexton KJ. In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol. 2012;14:584–92.
39. Ginovart N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol. 2005;7:45–52.
40. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009;315:683–96.
41. Pu YS, Huang CY, Kuo YZ, Kang WY, Liu G, Huang AM, et al. Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci. 2009;16:82.
42. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer. 2011;11:294.
43. 11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res. 2013;19:183–93.
44. Johansson L, Chen C, Thorell JO, Fredriksson A, Stone-Elander S, Gafvelin G, et al. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat Methods. 2004;1:61–6.
45. Arnér ES, Sarioglu H, Lottspeich F, Holmgren A, Böck A. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J Mol Biol. 1999;292:1003–16.
46. 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death. Biochim Biophys Acta. 1830;2013:2562–73.
47. 11C]methane. Appl Radiat Isot. 1997;48:153–7.
48. Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995–1000.
49. Aubele M, Spears M, Ludyga N, Braselmann H, Feuchtinger A, Taylor KJ, et al. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues. Br J Cancer. 2010;103:663–7.
50. 262 in Alzheimer’s disease. Neuromol Med. 2013;15:458–69.
51. Adams MC, Turkington TG, Wilson JM, Wong TC. A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol. 2010;195:310–20.